AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

172.310

+0.7400.43%

Volume:1.50M

Turnover:259.17M

Market Cap:82.52B

PE:-23.06

High:175.365

Open:172.800

Low:171.000

Close:171.570

52wk High:219.589

52wk Low:90.000

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.27

T/O Rate:0.31%

Dividend:4.12

Dividend Rate:2.39%

EPS(TTM):-7.473

EPS(LYR):-7.473

ROE:-15.83%

ROA:7.26%

PB:3.99

PE(LYR):-23.06

Loading ...

Overview Company News Filings

CSL Ltd - European Commission Adopts Decision to Revoke Marketing Authorisation for Tavneos in the European Union and European Economic Area Countries

THOMSON REUTERS

CSL Ltd - Tavneos Will no Longer be Available for Prescribing in the EU and Eea

THOMSON REUTERS

CSL Ltd - Committed to Implementing Decision in Full

THOMSON REUTERS

US FDA Approves First mRNA Flu Shot from Moderna

QBE Stock Leads 3 Australian Dividend Shares Offering Income and Quality

Simply Wall St.

CSL Sets Investor Briefing for Full-Year Results

iBio Names Endocrinologist Molly Carr as Chief Medical Officer

Australian Dividend Stocks Worth A Closer Look For Long Term Income

Simply Wall St.

CSL Stock And Australian Gold Miners Offering Dividend Yield Above 3%

Simply Wall St.

CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value

Simply Wall St.

CSL Stock And 2 Australian Dividend Shares Backed By Earnings

Simply Wall St.

Australian Shares Log Best Month Since February as Rate-hike Worries Ease

CSL Stock And QBE Shares For Dividend Income Above 3%

Simply Wall St.

Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?

Simply Wall St.

Asia Morning Call-Global Markets

ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally

MT Newswires Live

Australia's CSL Rises on Launching Trials for Patented Manufacturing Process

CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%

MT Newswires Live

Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement

Horizon 2 Technology Enables Greater Immunoglobulin Production

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/CSL.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":172.31,"timestamp":1788243120000,"preClose":171.57,"halted":0,"volume":1501636,"delay":0,"changeRate":0.004313108352276092,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.473058576207737,"marketStatus":"Not Yet Opened","change":0.74,"latestTime":"09-01 16:12:00 AEST","open":172.8,"high":175.365,"low":171,"amount":259171238,"amplitude":0.025442,"askPrice":172.31,"askSize":5,"bidPrice":172.2,"bidSize":250,"shortable":3,"etf":0,"ttmEps":-7.473058576207737,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":171.57,"dividendRate":0.023897,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":1.265648,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":171.57,"auctionPrice":172.33,"auctionVolume":317793,"auction":3,"marketStatus":"盘后竞价","timestamp":1788243005735}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.473059,"volumeRatio":1.265648,"shares":478911979,"dividePrice":4.1177,"high":175.365,"amplitude":0.025442,"preClose":171.57,"low":171,"week52Low":90,"pbRate":"3.99","psRate":"3.74","week52High":219.589,"institutionHeld":0,"latestPrice":172.31,"committee":0.960784,"eps":-7.473058576207737,"divideRate":0.023897,"volume":1501636,"delay":0,"ttmEps":-7.473058576207737,"open":172.8,"prevYearClose":170.408,"prevWeekClose":172.32,"prevMonthClose":171.57,"prevQuarterClose":114.74,"fiveDayClose":173.64,"twentyDayClose":128.83,"sixtyDayClose":99.47,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.018567360626050477},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657502897","title":"CSL Ltd - European Commission Adopts Decision to Revoke Marketing Authorisation for Tavneos in the European Union and European Economic Area Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502897?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996070,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44225J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502392","title":"CSL Ltd - Tavneos Will no Longer be Available for Prescribing in the EU and Eea","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502392?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44225J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","BK7501","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502318","title":"CSL Ltd - Committed to Implementing Decision in Full","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502318?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996070,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44225J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","BK7501","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657503965","title":"US FDA Approves First mRNA Flu Shot from Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503965","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657503965?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:17","pubTimestamp":1785982652,"startTime":"0","endTime":"0","summary":"US FDA approves first mRNA flu shot from ModernaAug 5 (Reuters)-The U.S. Food and Drug Administration has approved Moderna'sMRNA.Oflu vaccine for people aged 50 and older, the company said on Wednesda","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4N43Q1QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","BK7067","LU1989771016.USD","LU0128525689.USD","CSL.AU","AZN.UK","LU0757432116.USD","BK7508","LU1863844665.USD","LU0171276677.USD","LU0964806797.USD","IDNA","LU0545039389.USD","LU0289739699.SGD","LU0784383803.USD","LU0949170772.SGD","LGHT","LU0553294199.USD","LU1119994496.HKD","LU1153584641.USD","LU0738911758.USD","LU0122379950.USD","LU1989772840.SGD","LU2355687059.USD","LU1923622614.USD","MRNX","LU0158827948.USD","03165","LU1057294990.SGD","LU1267930813.SGD","LU2237443465.HKD","LU2539964713.USD","IE00BFTCPJ56.SGD","WDNA","MRNA","LU0310799852.SGD","LU0047473722.EUR","LU0496365809.HKD","LU1015430645.USD","LU1084165304.USD","LU1487256676.USD","BK4588","LU0823416689.USD","LU0784385170.HKD","LU2091194634.USD","BK7511","GNOM","LU2112291526.USD","MRNY","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639527","title":"QBE Stock Leads 3 Australian Dividend Shares Offering Income and Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639527","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639527?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:28","pubTimestamp":1785958120,"startTime":"0","endTime":"0","summary":"Dividend Powerhouses can appeal to investors who want current income backed by companies that keep paying, rather than just hoping for price swings. With global growth mixed, inflation signals uneven and central banks watching energy prices and wage trends, a focus on well covered, stable and growing dividends can help bring some structure to a portfolio. This Dividend Powerhouses screener looks for yields above 5% that are supported by the underlying business. In the sections that follow,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/qbe-stock-leads-3-australian-dividend-shares-offering-income","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/qbe-stock-leads-3-australian-dividend-shares-offering-income","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EVN.AU","FGDL","XAO.AU","SGDM","FEBU","PMDE","JDST","IAU","RING","GBUG","QBE.AU","AAAU","GLL","PPI","DECU","PHYS","BTGD","GDXD","BEGS","DGP","GLDM","GDXU","GDXY","XME","JNUG","PICK","GOAU","GLTR","IAUM","GOLY","SGOL","CSL.AU","UGL","BAR","DULL","SHNY","IAUI","DBC","GXDW","UYM","XKO.AU","XJO.AU","CEF","DUST","USG","GDX","GDXJ","VOTE","OUNZ","DZZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657598900","title":"CSL Sets Investor Briefing for Full-Year Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657598900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657598900?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:43","pubTimestamp":1785883409,"startTime":"0","endTime":"0","summary":"CSL sets investor briefing for full-year resultsCSL will release its 2026 full-year financial result on Aug. 18, 2026.Investor and analyst briefing set for 10:00 a.m. AEDT on Aug. 18, 2026; webcast at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL7sQz4c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7067","BK7501","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530463","title":"iBio Names Endocrinologist Molly Carr as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530463","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530463?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:06","pubTimestamp":1785841618,"startTime":"0","endTime":"0","summary":"iBio names endocrinologist Molly Carr as chief medical officeriBio named endocrinologist Molly Carr as chief medical officer to lead global clinical strategy, medical affairs, regulatory work for its ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLbLNm32:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0203345920.USD","LU1487256676.USD","SG9999014013.SGD","LU0203347892.USD","LU1302929846.USD","CSL.AU","LU0225771236.USD","BK4112","LU0545562505.USD","LU0225284248.USD","LU1645745479.HKD","LU0306806265.USD","IE00BN0W2W23.USD","LU1481599808.USD","LU0306807586.USD","IE00BWDBJ516.SGD","LU0575583348.USD","LU0161305163.EUR","LU0987226296.USD","LU1015430645.USD","LU1670756490.USD","IE00B64PRP62.GBP","LU0225283273.USD","LU2089984988.USD","IE00BGHQF748.EUR","NDAQ","BK4588","LU0321505439.SGD","BK4585","LU1228905037.USD","BK7501","BCDF","LU0971552830.HKD","IE00BKPKM429.USD","IBIO","LU1228905540.USD","LU1098665638.USD","LU2468319806.SGD","LU1309081286.SGD","LU1202635105.USD","IE00B3T34201.USD","LU1983299246.USD","LU1035777561.USD","IE00BN0W2T93.GBP","LU0109981661.USD","LU1400636491.USD","LU1046248800.SGD","GSK.UK","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656772588","title":"Australian Dividend Stocks Worth A Closer Look For Long Term Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2656772588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656772588?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:27","pubTimestamp":1785796057,"startTime":"0","endTime":"0","summary":"Dividend income has fresh appeal right now, with inflation readings easing in several regions and government bond yields swinging around as central banks weigh their next steps. For investors who want income that does not rely only on bond markets, the Dividend Powerhouses screener focuses on companies with a 5%+ yield that is well covered, growing and stable. That combination can help you target cash flow while keeping an eye on sustainability. In this article you will see three of the...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/australian-dividend-stocks-worth-a-closer-look-for-long-term","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/australian-dividend-stocks-worth-a-closer-look-for-long-term","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","JDST","PMDE","SHNY","XKO.AU","SPHQ","IAUI","AAAU","GLDM","GBUG","OUNZ","XJO.AU","DGP","GLL","GDXD","BTGD","VIG","NST.AU","UYM","SGOL","GDXU","BAR","JNUG","XAO.AU","GOAU","IAUM","GOLY","USG","EVN.AU","RING","BEGS","GDXJ","SGDM","DBC","DZZ","GDX","DUST","GLTR","PHYS","DULL","UGL","PPI","CEF","IAU","GDXY","PICK","FGDL","VOTE","XME","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656345864","title":"CSL Stock And Australian Gold Miners Offering Dividend Yield Above 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656345864","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656345864?lang=en_us&edition=fundamental","pubTime":"2026-08-03 02:13","pubTimestamp":1785694430,"startTime":"0","endTime":"0","summary":"Global inflation, interest rate uncertainty and uneven growth across regions have pushed many investors to pay closer attention to steady income rather than chasing fast-moving stories. That is where Dividend Powerhouses 3%+ Yield stocks can help. The screener focuses on companies with dividend yields above 5% that appear well covered, growing and relatively stable, which can be appealing when bond markets and energy prices are pulling sentiment in different directions. In this article, you...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-australian-gold-miners-offering-dividend-yield","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-australian-gold-miners-offering-dividend-yield","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BAR","GDXU","XME","BTGD","DULL","GOLY","OUNZ","USG","DZZ","JDST","SGDM","DGP","FGDL","BEGS","JNUG","NST.AU","BBOZ.AU","PPI","XKO.AU","GBUG","GLTR","IAUM","GDXJ","DBC","CSL.AU","IGLD","CSL","GLL","IAUI","PHYS","GDX","UYM","UGL","DUST","RING","CEF","VIG","GDXY","IAU","XJO.AU","SHNY","GLDM","GOAU","AAAU","EVN.AU","GDXD","STW.AU","PICK","SGOL","XAO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656194823","title":"CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2656194823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656194823?lang=en_us&edition=fundamental","pubTime":"2026-08-02 01:23","pubTimestamp":1785604990,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has drawn fresh attention after reporting positive top-line Phase 3b results for its hereditary angioedema therapy ANDEMBRY in children aged 2 to 11 years, supporting potential expanded pediatric use.\nSee our latest analysis for CSL.\nThe ANDEMBRY update comes as CSL trades at A$123.06, with a 7 day share price return of 7.74% and a year to date share price decline of 28.44%. The 1 year total shareholder return is down 52.25%, pointing to weak long term momentum despite a recent...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-following-andembry-trial-results-still-looks-chea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-following-andembry-trial-results-still-looks-chea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","LU1169590202.USD","SG9999004303.SGD","SGXZ23171101.USD","BK4086","CSL","CSL.AU","LU0728928796.USD","LU1169589451.USD","BK7508","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656396122","title":"CSL Stock And 2 Australian Dividend Shares Backed By Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2656396122","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656396122?lang=en_us&edition=fundamental","pubTime":"2026-08-01 00:16","pubTimestamp":1785514612,"startTime":"0","endTime":"0","summary":"With inflation, interest rate questions and energy prices all pulling markets in different directions, many investors are looking for income that feels steadier than short term sentiment. Dividend Powerhouses, sometimes called Dividend Aristocrats, focus on companies with yields above 5% that are covered by earnings, growing and relatively stable. That combination can appeal if you want your portfolio to be paid while you wait for clearer signals from central banks and growth data. This...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-backed-by-earning","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-backed-by-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XAO.AU","XKO.AU","CSL","XJO.AU","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655435336","title":"Australian Shares Log Best Month Since February as Rate-hike Worries Ease","url":"https://stock-news.laohu8.com/highlight/detail?id=2655435336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655435336?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:25","pubTimestamp":1785482759,"startTime":"0","endTime":"0","summary":"REFILE-Australian shares log best month since February as rate-hike worries easeRemoves extraneous word from fourth bulletS&P/ASX 200 edges up 0.1% on FridayBenchmark logs best month since FebruaryASX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7507","FMG.AU","LU0971552830.HKD","LU0831103253.SGD","LU0171293334.USD","LU0264606111.USD","LU0612318385.USD","RIO.UK","SG9999001143.SGD","LU0612318971.USD","LU0266512127.USD","LU0456854461.SGD","LU0708995401.HKD","BK7511","IE0034235071.USD","LU1078025761.USD","LU1309081286.SGD","LU0289960550.SGD","LU0572940350.SGD","FDIQ","RIO.AU","IE00B3M56506.USD","LU0971552673.USD","LU0345780950.USD","LU0175139822.USD","LU0320765059.SGD","LU0654597011.USD","BK4112","LU0109391861.USD","BK7040","LU0390134368.USD","MSCI","WOW.AU","LU0955669360.SGD","IE00BQJZX424.USD","LU0330918003.SGD","LU0630314457.HKD","BK7129","BK4585","LU0572939691.SGD","LU1046248800.SGD","LU0511384066.AUD","CSL.AU","LU0672654240.SGD","LU2265009873.SGD","BHP.AU","LU1023059493.AUD","LU0345777147.USD","LU1302929846.USD","SG9999002521.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655809269","title":"CSL Stock And QBE Shares For Dividend Income Above 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655809269","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655809269?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:14","pubTimestamp":1785420860,"startTime":"0","endTime":"0","summary":"Dividend Powerhouses with 5%+ yields and solid coverage can be especially appealing when global growth looks mixed, inflation stays uneven, and central banks keep investors guessing on rates. Reliable income from well covered and stable dividends can help smooth out some of that noise and give you a clearer sense of what you are getting paid to wait. This article focuses on three stocks from the Dividend Powerhouses screener that combine higher yields with a history of maintaining and growing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-qbe-shares-for-dividend-income-above-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-qbe-shares-for-dividend-income-above-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PHYS","USG","DULL","IAU","JDST","AAAU","CSL.AU","DBC","OUNZ","GDX","GOLY","GBUG","DGZ","DZZ","CEF","GDXD","GLDY","PPI","YGLD","BAR","RING","GDXY","GLL","IAUM","BTGD","BGLD","DUST","SGOL","BEGS","GDXU","SGDM","IAUI","DGP","GDXJ","IGLD","GOAU","GLTR","XME","SHNY","FGDL","GLDM","CSL","UGL","QBE.AU","KGLD","PICK","EVN.AU","UYM","JNUG","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655296468","title":"Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2655296468","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655296468?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:27","pubTimestamp":1785382062,"startTime":"0","endTime":"0","summary":"CSL recently reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 with hereditary angioedema, showing a safety profile in line with earlier studies and that most participants remained attack-free over 12 months.\nThe company now plans regulatory filings to extend ANDEMBRY’s indication to younger children, potentially widening treatment options in a part of the HAE population where approved long-term prophylactic choices remain limited.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0728928796.USD","BK7508","LU1169589451.USD","SG9999004303.SGD","SGXZ23171101.USD","BK7067","LU1169590202.USD","BK4086","BK7511","BK7501","CSL","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655818139","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2655818139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655818139?lang=en_us&edition=fundamental","pubTime":"2026-07-30 02:32","pubTimestamp":1785349969,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsJuly 30 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**9,038.6090.80NZX 50**13,976.67114.74DJIA51,932.67-814.65NIKKEI**61,434.19-930.73Nasdaq24,779.13","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V1ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481600234.SGD","RIO.AU","BK4112","LU0955669360.SGD","FDIQ","IE00B3M56506.USD","LU0898667661.SGD","SG9999001143.SGD","LU0266512473.USD","LU1267930730.SGD","LU0831103253.SGD","LU0011963245.USD","LU0345781412.USD","LU2210149790.SGD","LU0289960550.SGD","LU0708995401.HKD","LU2265009873.SGD","LU0264606111.USD","LU1023059493.AUD","LU0171293334.USD","SG9999002521.SGD","LU0612318971.USD","LU2095319765.USD","LU1064927863.SGD","LU0955648018.USD","LU0320765059.SGD","LU0266512127.USD","LU1130305938.SGD","LU1804176565.USD","IE0034235071.USD","RIO.UK","LU0572940350.SGD","LU0390134368.USD","MSCI","BK5111","BK4585","LU0289739343.SGD","LU0654597011.USD","CSL.AU","LU1309081286.SGD","LU0345780950.USD","LU0345777147.USD","BK7095","LU0456854461.SGD","LU0572939691.SGD","LU0161305163.EUR","LU0345777659.USD","BK7507","LU0971552673.USD","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655830439","title":"ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2655830439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655830439?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:58","pubTimestamp":1785293913,"startTime":"0","endTime":"0","summary":"Healthcare stocks jumped nearly 4%, leading a broad-based rally at midday Wednesday.CSL  gained almost 7% in recent trade following news that it will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process.Meanwhile, the financial sector edged up nearly 1%.Commonwealth Bank  shares inched up in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029874061.USD","BK4137","CBA.AU","BK7501","BK7067","BK7511","CSL.AU","HCSG","DBB","XBI","XLV","BK4588","BK7508","LU0128526141.USD","BK7135","BK4581","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783450","title":"Australia's CSL Rises on Launching Trials for Patented Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783450","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655783450?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:54","pubTimestamp":1785286492,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises on launching trials for patented manufacturing process** Shares of biotechnology major CSLCSL.AXrise 5.6% to A$126.59, their highest since July 9** Stock on track for best d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V02K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655083457","title":"CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655083457","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655083457?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:53","pubTimestamp":1785286428,"startTime":"0","endTime":"0","summary":"CSL  will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process, according to a Wednesday Australian bourse filing.The company said it expects clinical activities to start in mid-2027.The process enables greater production of immunoglobulin from the same base amount of plasma, per the filing.The company said it will obtain clinical evidence to support and finalize regulatory approval processes for Horizon 2 after its engagements with the US Food and Drug Administration and European Medicines Agency.CSL's shares rose nearly 6% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGXZ23171101.USD","BK7501","SG9999004303.SGD","BK7067","BK4086","CSL","BK7508","CSL.AU","LU1169590202.USD","LU1169589451.USD","BK7511","LU0728928796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137947072","title":"Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1137947072","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137947072?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:14","pubTimestamp":1785284061,"startTime":"0","endTime":"0","summary":"Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655883986","title":"Horizon 2 Technology Enables Greater Immunoglobulin Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2655883986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655883986?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}